Corvus reports Q2 2026 results, updates soquelitinib pipeline progress

Corvus Pharmaceuticals reported a business update alongside its second quarter 2026 financial results on August 6, 2026. The company said it continues to enroll patients across multiple sites in a registrational Phase 3 trial of soquelitinib in relapsed/refractory peripheral T-cell lymphoma, a randomized controlled study expected to enroll 150 patients comparing soquelitinib against physicians' choice of belinostat or pralatrexate chemotherapy¹, with progression free survival as the primary endpoint¹. Soquelitinib holds Orphan Drug Designation for T cell lymphoma and Fast Track designation for adult relapsed or refractory PTCL patients after at least two prior lines of therapy¹, granted because no FDA fully approved agents exist for relapsed/refractory PTCL¹.

In atopic dermatitis, Corvus is enrolling the SIERRA1 Phase 2 randomized, blinded, placebo-controlled trial, expected to enroll about 200 patients across four 50-patient cohorts testing soquelitinib at 200 mg once daily, 200 mg twice daily, and 400 mg once daily against placebo¹. The company's China partner, Angel Pharmaceuticals is enrolling a Phase 1b/2 trial in moderate-to-severe atopic dermatitis, with cohort 1 results anticipated later in 2026¹. Corvus said it plans to start a Phase 1b trial in hidradenitis suppurativa and a Phase 2 trial in asthma later this year¹, while Angel Pharma anticipates starting its own Phase 2 asthma trial in early 2027¹.

On financing, Corvus invested $5.0 million in a $13.5 million equity round for Angel Pharma, intended to support the ongoing atopic dermatitis trial and the new asthma study¹. Corvus reported cash, equivalents and marketable securities of $215.2 million at quarter end, up from $56.8 million at year-end 2025, and said this is expected to fund operations into the second quarter of 2028¹.